Pfizer Adjusts Coronavirus Vaccine Efficacy Data
A final analysis of data from a Phase III clinical trial of the coronavirus vaccine being developed by Pfizer and BioNTech has shown that it is 95% effective even in the elderly. In terms of safety, the vaccine does not cause any serious adverse events, CNN reports.
According to the collected data, 170 cases of COVID-19 infection were identified among the study participants, with 162 in volunteers from the placebo group. Earlier, the company talked about efficiency at the level of 90%, but new data made it possible to adjust this indicator. It is important that among people over 65 years of age, the effectiveness of the vaccine also exceeded 94%. More than 43.6 thousand volunteers take part in the study.
Pfizer is expected to submit the paperwork required to register the vaccine with the FDA in the coming days. Already in 2020, the company intends to release up to 50 million doses of the vaccine, and in 2021 the volume will produce up to 1.3 billion doses of the drug.